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The Abstract: The U.S. Food and Drug Administration recently added potentially fatal Listeria monocytogenes infection to the list of opportunistic infections that can occur in patients who receive tumor necrosis factor inhibitor therapy. In this study, the first reported case of L monocytogenes cholecystitis associated with etanercept use is described. It also appears that tumor necrosis factor inhibitor therapy likely increases the risk for Listeria cholecystitis. Clinicians need to be aware of this association when selecting antimicrobial therapy for these patients. Two days after discharge, he was readmitted to the hospital because ascitic fluid was draining through his cholecystectomy ports and the microbiology laboratory reported that a bile culture obtained intraoperatively was growing L monocytogenes. Blood cultures that were negative during the first admission were repeated and were negative once again. Signs and symptoms of CNS infection were absent and a decision was made to refrain from performing a lumbar puncture. The patient was given ampicillin, 2 g every 6 hours intravenously for 5 days and then declined additional intravenous therapy. He was then discharged on on oral therapy for 4 more weeks. During the antibiotic treatment period, his TNFIT was withheld. The patient was seen in follow-up 1 month after stopping the antibiotic and had returned to his baseline status.
Key

Discussion
Listeria monocytogenes, a facultative anaerobic grampositive rod, has been receiving more attention lately because of its role in recent outbreaks of food-born illnesses. Listeria monocytogenes infection initiates with a gastroenteritis that often goes undiagnosed. The organism may be controlled at the latter stage or may go on to disseminate. In patients with impaired cellular immunity, and especially those patients receiving TNFIT, Listeria infections have been reported with increasing frequency and have been shown in many individuals to cause significant morbidity and mortality. 4 Allerberger et al2 found that 2 of 467 L monocytogenes isolates were obtained from the gallbladder. Table 1 lists the clinical characteristics of our case and another 5 cases of L monocytogenes cholecystitis reported in the literature. Three patients had rheumatoid arthritis as an underlying condition requiring TNFIT and 2 of those received infliximab. All patients underwent a cholecystectomy combined with antibiotic treatment. Four of the 6 patients received ampicillin or penicillin. Bile cultures grew the organism in 5 of the 6 patients. Pathology reports revealed inflammation of the gallbladder compatible with cholecystitis in 4 patients and were not reported in 2 others. Four of these 6 patients had prolonged and complicated hospital courses; 1 patient died.
Since its introduction in 1998, infliximab, the first tumor necrosis factor (TNF) inhibitor, has been used to treat a number of autoimmune diseases. Tolerability and therapeutic efficacy of both infliximab and etanercept are good, and the number of patients receiving these agents is increasing steadily.5 It is well known that TNFIT increases ones susceptibility to a wide variety of opportunistic pathogens including mycobacteria, fungi and several viruses and bacteria. The latter pathogens require an intact T-helper cell response for recovery.6 Among the reported bacterial pathogens, Listeria species have been recognized with increasing frequency. The U.S. Food and Drug Administration reported 26 cases of serious L monocytogenes infections in the literature, including 7 deaths, among patients treated with a TNF inhibitor.4 A systematic review and meta-analysis also confirmed that TNFIT increased the risk for serious infection.7 Our case and 2 previous case reports confirmed the risk for Listeria infection associated with TNFIT in patients with rheumatoid arthritis and, in particular, the risk of this pathogen as a causative organism in biliary tract disease.
Begley et al8 postulated that Listeria may be responsible for enhanced biofilm formation in bile, which may contribute to the survival of this pathogen in the biliary tree. Bile tends to be resistant to bacterial growth. Eimerman9 characterized the growth of Listeria in bile and the murine gallbladder. Listeria apparently possesses resistance genes that allow it to overcome bile's inherent bacterial toxicity. Given its tropism for the gallbladder, it is perhaps surprising that Listeria biliary infections are not observed more frequently. Nevertheless, the precise pathogenesis of Listeria cholecystitis is unknown.
Although, the Gram's stain of the gallbladder wall in our patient did not reveal gram-positive bacilli, the histological examination revealed inflammation of the gallbladder compatible with cholecystitis. In addition, the bile Gram's stain showed gram-positive bacilli and the cultures grew L monocytogenes suggesting its pathological role. The U.S. Food and Drug Administration recently added potentially fatal Listeria infection to the list of opportunistic infections that occur in patients who receive TNFIT. 4 We believe that in suspected biliary tract infection in a patient who is being treated with TNFIT, strong consideration should be given to an antimicrobial agent that is able to cross the blood-brain barrier and has activity against Listeria.
In summary, a patient who manifests signs and/or symptoms suggestive of infection during TNFIT must receive a rapid and careful evaluation, with a high suspicion for unusual pathogens and in particular L monocytogenes. In addition, TNFIT likely increases the risk for Listeria cholecystitis. Physicians should consider L monocytogenes as a cause of cholecystitis in patients who are receiving TNFIT to initiate appropriate treatment and hopefully reduce the potentially severe morbidity and mortality associated with this pathogen.
